ROCHESTER MEDICAL CORPORATION 
By STEWARTVILLE, Minn., Jan. 29, 2013 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ: ROCM) today announced operating results for its first quarter ended December 31, 2012.
(Logo: http://photos.prnewswire.com/prnh/20121228/CG34999LOGO)
The Company reported record sales of $17,252,000 for the current quarter compared to $13,973,000 for the first quarter of last year. The Company also reported net income of $1,012,000 or $.08 per diluted share compared to net loss of ($75,000) or ($.01) per diluted share for the same period last year.
The 23% increase resulted from a 24% increase in Rochester Medical Direct Sales and a 19% increase in Private Label Sales. The growth percentages were essentially the same on a constant currency basis which assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations.
Net Income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter was $1,425,000 or $.11 per diluted share compared to Non-GAAP Net Income of $285,000 or $.02 per diluted share for the first quarter of last year. The increase for the current quarter was primarily due to increased gross profits as a result of higher sales revenues and a reduction in operating expenses related to the sales and marketing of the Foley product line, somewhat offset by higher first quarter administrative expenses related to year end activities.
Commenting on the quarterly results, Rochester Medical's CEO and President Anthony J. Conway said, "Our Direct Sales continue to grow nicely, particularly in the United States and the United Kingdom. U.S. Direct Sales were up 41% and U.K. Direct Sales were up 26%. Intermittent Catheter sales, in particular, continue to grow at a very strong pace.
"Cash generated by operations continues to meet our expectations. This quarter our cash and equivalents increased by $2.3 million. We anticipate the Company's new manufacturing facility, which is now under construction, will be fully funded from within."
Conway concluded, "We are pleased with the quarterly results and look forward to an active and successful 2013."
Conference Call and Webcast
The Company will hold a quarterly conference call on Tuesday, January 29, 2013 to discuss its earnings report. The call will begin at 3:30 p.m., Central Time (4:30 p.m., Eastern Time).
This call is being webcast by Thomson Reuters and can be accessed at Rochester Medical's website at www.rocm.com. To listen live to the conference call via telephone, call:
Domestic: 888 679 8037
International: 617 213 4849
Pass code: 93735191
Preregistration:
https://www.theconferencingservice.com/prereg/key.process?key=P949QXBTJ
Replay will be available for seven days at www.rocm.com or via telephone at:
Domestic: 888 286.8010
International: 617 801.6888
Pass code: 26318672
Individual investors can listen to the call at www.fulldisclosure.com, Thomson Reuters individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
Forward-Looking Statements
This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the future financial and operating results of Rochester Medical. Such statements are based on currently available information, operating plans and management's expectations about future events and trends. Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, and our level of success in increasing Rochester Medical Direct Sales revenue, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2012, and quarterly reports on Forms 10-Q. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
Rochester Medical has provided Non-GAAP Net Income in addition to net income calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Similarly, constant currency represents reported sales with the cost/benefit of currency movements removed. Management uses the measure to understand the growth of the business on a constant dollar basis, as fluctuations in exchange rates can distort the underlying growth of the business both positively and negatively. While we recognize that foreign exchange volatility is a reality for a global company, we routinely review our Company performance on a constant dollar basis, and we believe this also allows our shareholders to understand better our Company's growth trends.
Non-GAAP Net Income and constant currency are not measures of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income and constant currency are not comparable to information provided by other companies. Non-GAAP Net Income and constant currency have limitations as analytical tools and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of GAAP Net Income and Non-GAAP Net Income, and reconciliations of sales under GAAP and sales on a constant currency basis, are presented at the end of this press release.
About Rochester Medical Corporation
Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600 or Parice Halbert, CFA, at Westwicke Partners (443) 213-0500. More information about Rochester Medical is available on its website at http://www.rocm.com.
Rochester Medical Corporation
Press Release - F13 First Quarter
Condensed Consolidated Statements Of Operations
(unaudited)
Three months ended
December 31,
------------
2012 2011
---- ----
Sales $17,252,008 $13,972,607
Cost of sales 8,778,760 6,861,468
--------- ---------
Gross profit 8,473,248 7,111,139
Gross
profit % 49.1% 50.9%
Costs and expense:
Marketing
and
selling 4,549,044 4,668,062
Research and
development 339,158 376,269
General and
administrative 2,207,542 2,087,537
Total operating expenses 7,095,744 7,131,868
--------- ---------
Income (loss) from operations 1,377,504 (20,729)
Other income (expense) 10,263 (91,070)
Net income (loss) before income taxes 1,387,767 (111,799)
Income tax expense (benefit) 375,622 (36,452)
------- -------
Net income (loss) $1,012,145 $(75,347)
========== ========
Net income (loss) per common share - Basic $0.08 $(0.01)
===== ======
Net income (loss) per common share - Diluted $0.08 $(0.01)
===== ======
Weighted Average Shares:
Basic 12,038,232 12,136,125
Weighted Average Shares:
Diluted 12,396,930 12,136,125
Rochester Medical Corporation
Press Release - F13 First Quarter
Condensed Consolidated Balance Sheets
(unaudited)
December 31, September 30,
2012 2012
---- ----
Assets
Current Assets
Cash and
equivalents $16,311,106 $13,921,363
Marketable
securities 6,739,272 6,779,695
Accounts
receivable 9,458,473 11,008,429
Inventories 9,624,926 9,883,650
Prepaid
expenses and
other assets 1,601,513 1,726,908
Deferred
income tax
asset 1,304,214 1,287,177
--------- ---------
Total current assets 45,039,504 44,607,222
Property and
equipment, net 12,280,407 11,862,072
Deferred income
tax asset 1,086,322 1,030,994
Intangible assets,
net 9,276,256 9,377,355
Goodwill 9,210,602 9,053,091
Total Assets $76,893,091 $75,930,734
Liabilities and Stockholders' Equity
Current
liabilities:
Accounts
payable $2,716,170 $3,070,329
Accrued
expenses 2,558,117 3,427,397
--------- ---------
Total current
liabilities 5,274,287 6,497,726
Long-term
liabilities 1,164,819 1,137,212
Stockholders'
equity 70,453,985 68,295,796
Total Liabilities
and Stockholder
Equity $76,893,091 $75,930,734
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Net Income to Non-GAAP Net Income
For the Three months ended
December 31, 2012 and 2011
(unaudited)
Three months ended
December 31,
------------
2012 2011
---- ----
GAAP Net Income
(Loss) as
Reported $1,012,000 $(75,000)
========== ========
Net Income
(Loss) Per
Share -
Diluted as
Reported $0.08 $(0.01)
===== ======
Adjustments for
non-recurring
unusual items:
Severance costs
(1) 111,000 -
------- ---
Subtotal 111,000 -
Adjustments for
recurring non-
cash expenses:
Intangible
amortization
(2) 155,000 158,000
ASC 718
compensation
expense (3) 147,000 202,000
------- -------
Subtotal 302,000 360,000
Non-GAAP Net
Income $1,425,000 $285,000
========== ========
Non-GAAP
Diluted EPS $0.11 $0.02
===== =====
Weighted
Average Shares
-Diluted 12,396,930 12,311,866
(1) Severance costs associated with our
exiting of the Foley Catheter market. The
company
announced they were exiting the Foley Catheter
market on November 6, 2012. This adjustment
adds
back severance costs of certain employees for
the three months ended December 31, 2012.
The gross
amount of the severance costs for the three
months ended December 31, 2012 is $152,000
net of taxes of
$41,000 for a net amount of $111,000
(2) Amortization of the intangibles acquired
in June 2006 asset acquisition from Coloplast
AS and Mentor
Corporation and the intangibles acquired in
the January 2011 acquisition of Laprolan from
Fornix N.V.
Management believes these assets are
appreciating. This adjustment adds back
amortization
expense for the three months ended December
31, 2012 and 2011 related to certain
intangibles.
The gross amount of amortization expense for
the three months ended December 31, 2012 and
2011 is
$213,000 and $218,000 net of taxes of $58,000 and $60,000 for net amounts of $155,000 and $158,000
respectively.
(3) Compensation expense mandated by ASC 718.
This adjustment adds back the compensation
expense
recorded for stock options granted to
employees and directors that vested during
the three months ended
December 31, 2012 and 2011. The gross amount
of compensation expense for the three months
ended
December 31, 2012 and 2011 is $202,000 and
$316,000 net of taxes of $55,000 and $114,000
for net
amounts of $147,000 and
$202,000 respectively.
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Revenue to Non-GAAP Revenue in Constant
Currency
For the Three months ended
December 31, 2012 and 2011
(unaudited)
Three months ended
December 31,
------------
2012 2011
---- ----
GAAP
Sales
as
Reported $17,252,008 $13,972,607
=========== ===========
British
Sterling
Exchange
rate
as
reported 1.61 1.57
==== ====
Euro
Exchange
rate
as
reported 1.30 1.35
==== ====
Constant
Currency
Sales $17,252,008 $13,992,905
=========== ===========
(1)
Exchange
rate
used
for
Constant
Currency
Purposes 1.61 1.61
==== ====
(2)
Exchange
rate
used
for
Constant
Currency
Purposes 1.30 1.30
==== ====
Net
Effect
of
Constant
Currency
Illustration
-
British
Sterling $ - $105,430
========================= ========
Net
Effect
of
Constant
Currency
Illustration
-
Euros $ - $(85,132)
========================= ========
Total
Net
Effect
of
Constant
Currency
Illustration $ - $20,298
========================= =======
(1) For illustrative purposes
constant currency translates
prior period foreign sales at
current exchange rates. For
Rochester Medical Corporation
this is the conversion rate
of British pounds to US
dollars. The rate represents
the average exchange rate for
the respective three month
period.
(2) For illustrative purposes
constant currency translates
prior period foreign sales at
current exchange rates. For
Rochester Medical Corporation
this is the conversion rate
of Euros to US dollars. The
rate represents the average
exchange rate for the
respective three month
period.
SOURCE Rochester Medical Corporation
